An increase in glucocorticoid levels and down-regulation of BDNF (brain-derived neurotrophic factor) are supposed to be involved in the pathophysiology of depressive disorders. However, possible crosstalk between glucocorticoid-and BDNF-mediated neuronal functions in the CNS has not been elucidated. Here, we examined whether chronic glucocorticoid exposure influences BDNF-triggered intracellular signaling for glutamate release via a glutamate transporter. We found that chronic exposure to dexamethasone (DEX, a synthetic glucocorticoid) suppressed BDNF-induced glutamate release via weakening the activation of the PLC-␥ (phospholipase C-␥)/Ca 2؉ system in cultured cortical neurons. We demonstrated that the GR (glucocorticoid receptor) interacts with receptor tyrosine kinase for BDNF (TrkB). Following DEX treatment, TrkB-GR interaction was reduced due to the decline in GR expression. Corticosterone, a natural glucocorticoid, also reduced TrkB-GR interaction, BDNF-stimulated PLC-␥, and BDNF-triggered glutamate release. Interestingly, BDNF-dependent binding of PLC-␥ to TrkB was diminished by DEX. SiRNA transfection to induce a decrease in endogenous GR mimicked the inhibitory action of DEX. Conversely, DEX-inhibited BDNF-activated PLC-␥ signaling for glutamate release was recovered by GR overexpression. We propose that TrkB-GR interaction plays a critical role in the BDNF-stimulated PLC-␥ pathway, which is required for glutamate release, and the decrease in TrkB-GR interaction caused by chronic exposure to glucocorticoids results in the suppression of BDNF-mediated neurotransmitter release via a glutamate transporter.
induced glutamate release occurs via a glutamate transporter in a Na ϩ -dependent manner as we previously reported (18) . BDNF-induced glutamate release depends on an intracellular Ca 2ϩ increase via IP 3 -sensitive Ca 2ϩ channels (IP 3 receptor) (18) . As expected, chronic DEX treatment weakened BDNFincreased Ca 2ϩ ( Fig. 1B and Fig. S4 A and B) . We confirmed that U73122 (a PLC-␥ inhibitor) and xestospongin C (Xest C, an IP 3 receptor inhibitor) blocked BDNF-increased Ca 2ϩ , although BDNF still increased Ca 2ϩ in the presence of APV (an NMDA receptor inhibitor), CNQX (an AMPA receptor inhibitor), or bicuculline (a GABA A receptor inhibitor) (Fig. S4 C and D) , indicating the importance of the PLC-␥/IP 3 pathway. We confirmed that both U73122 and Xest C blocked BDNF-induced glutamate release in the control and DEX-treated cultures (Fig.  S4E ). These results suggest that BDNF-induced glutamate release depends on the PLC-␥ pathway.
Next, we focused on PLC-␥ activation (phosphorylation). A significant decline in BDNF-activated PLC-␥ following chronic DEX exposure was observed, although TrkB (upstream of PLC-␥) was equally activated by BDNF with or without DEX ( Fig. 1 Ci and ii) . In other pathways activated by TrkB, DEX did not change activation of Akt (pAkt, phosphorylated Akt) or ERK1/2 (pERK1/2) stimulated by BDNF (Fig. 1Ciii) .
Recently, activation of TrkB signaling within several hours of glucocorticoid exposure was reported (25) . Indeed, TrkB, PLC-␥, Akt, and ERK1/2 were activated by short-term application of glucocorticoids (DEX or corticosterone) ( Fig. S5 A and  B) . These activations reached their maximum at 2-4 h after the application and returned to the basal level at 6 h. As expected, BDNF induced much higher activation of TrkB signaling (including PLC-␥, Akt, and ERK1/2) compared with that induced by sole acute DEX (2 h) or corticosterone (2 h) exposure ( Fig.  S6 A-C). In contrast to chronic exposure, such a short-term treatment with DEX (2 h) or corticosterone (2 h) did not affect the exogenous BDNF-stimulated TrkB signaling, including PLC-␥. Subsequently, we focused on the suppression of BDNFdependent PLC-␥ signaling for glutamate release after longlasting glucocorticoid exposure.
DEX-Dependent GR Down-Regulation Was Involved in the Suppressed
Responses to BDNF. To investigate the mechanisms underlying the DEX-suppressed responses to BDNF, the possible involvement of the GR was examined. When DEX was coapplied with RU486 (a GR antagonist), BDNF-stimulated PLC-␥ activation and glutamate release were not inhibited ( Fig. 2 Ai and ii and Fig.  2B ), suggesting that DEX acts via the GR. Thus, endogenous GR expression after DEX addition was examined. Marked downregulation of the GR was observed following DEX application for 24 to 48 h (Fig. 2C) . DEX induced GR down-regulation in a dose-dependent manner ( Fig. 2 Di and ii), while the mineral corticoid receptor (MR, the other receptor for glucocorticoid) and TUJ1 (class III ␤-tubulin, a neuronal marker) expression was intact (Fig. 2Di) . Immunocytochemistry with antimicrotubule-associated protein 2 (MAP2) and anti-GR antibodies was performed, and the quantification of the staining indicated a DEX-dependent GR reduction in neurons (Fig. 2 Ei-vii). As expected, RU486 recovered GR down-regulation by DEX ( Fig. 2 Fi and ii) . Corticosterone also down-regulated the GR and BDNF-induced glutamate release (Fig. S7 A-C) . Moreover, the suppression of BDNF-activated PLC-␥ by corticosterone was also observed (Fig. S7 D and E) . We confirmed that the GR was markedly reduced in the homogenates of the cerebral cortex prepared from rats after DEX administration, although the MR level was intact (Fig. S7 F and G) . These results suggested that the inhibitory action of glucocorticoid results from the downregulation of the GR.
Then, the effects of GR overexpression were examined. After viral infection, about 85% of MAP2-positive cells in either the control (GFP) or GR-overexpressing (GR and GFP) cultures were GFP-positive, indicating that the majority of neurons were infected (Fig. 3Ai) . Blotting with anti-GR and anti-GFP antibodies showed GR overexpression (Fig. 3Aii) , which enhanced BDNF-induced glutamate release (Fig. 3B) . DEX failed to reduce BDNF-activated PLC-␥ in GR-infected cultures ( Fig. 3 Ci and ii). Next, siRNA was used to examine the function of endogenous GR. Approximately 60% of endogenous GR was depleted by GR-siRNA (Fig. 3D) , and BDNF-induced glutamate release was decreased in GR-siRNA-transfected cultures (Fig.  3E) . GR-siRNA reduced BDNF-activated PLC-␥ ( Fig. 3 Fi and ii) but not pAkt or pERK1/2 ( Fig. S8 A-C) . These results suggest that the amount of GR expression is critical for BDNFstimulated PLC-␥ signaling and glutamate release.
DEX Decreased TrkB-GR Interaction and Binding of PLC-␥ to TrkB.
How does chronic DEX interrupt PLC-␥ signaling? Initially, endogenous PLC-␥, TrkB, or BDNF expression after DEX exposure was examined; however, the levels of these proteins were intact ( Fig. S9 A and B) . The level of TrkB on the cell surface was also unchanged ( Fig. S9 C and D) . Subsequently, the possible interaction between GR and TrkB was investigated. Following immunoprecipitation with anti-GR antibody, coprecipitated TrkB was found (Fig. 4Ai) . The degree of coprecipitated TrkB was not changed by BDNF and/or DEX ( Fig. 4 Aii and iii). Significant coprecipitated GR after immunoprecipitation of TrkB was also observed (Fig. 4Bi) . Remarkably, DEX reduced the coprecipitated GR with or without BDNF application ( Fig. 4 Bii and iii). In the control, a BDNF-dependent slight increase in the coprecipitated GR was observed. To inspect the specificity of the interaction, we used a competitive peptide to block TrkB immunoprecipitation. The peptide, containing a sequence for the epitope of the antibody, blocked the immunoprecipitation of TrkB and the coprecipitation of the GR (Fig. 4C) . Moreover, GR overexpression increased TrkB-GR interaction, and GRsiRNA transfection decreased TrkB-GR interaction ( Fig. S10 
A-C). Corticosterone also reduced TrkB-GR interaction (Fig. S10 D and E).
Immunocytochemical analysis showed that the merged level of the GR-and TrkB-positive signal was diminished because chronic DEX exposure decreased the GR levels ( Fig.  S11 A and B) . In contrast to chronic exposure, acute DEX or corticosterone had no effect on TrkB-GR interaction with or without BDNF (Fig. S12) . Interestingly, BDNF-induced binding of PLC-␥ to TrkB decreased due to chronic DEX (Fig. 4 Di and ii). Marked reduction in TrkB-GR interaction in the homogenates of the cerebral cortex prepared from rats treated with DEX injection was confirmed (Fig. 4 Ei and ii).
To further assess TrkB-GR interaction, 3 types of GR plasmids containing His tags were constructed (Fig. 5A) . GR-FL (full length), GR-N (including DNA binding site), GR-C (including ligand binding site), and GFP (con) were transfected into SH-SY5Y cells. As the anti-GR antibody recognized GR-FL and GR-N but not GR-C (Fig. 5Bi , the epitope for the antibody exists in the N-terminal region of GR), blotting with anti-His antibody was also performed with total lysates (Fig. 5Bii) . After immunoprecipitation of TrkB, blotting with anti-GR (Fig. 5Biii) , anti-TrkB (Fig. 5 Biii and iv) , and anti-His antibodies (Fig. 5Biv) was conducted. GR-FL and GR-N were coprecipitated; however, GR-C failed to interact with TrkB, indicating the importance of the N-terminal region of the GR. BDNF-activated PLC-␥ in GR-FL-transfected SH-SY5Y cells was enhanced compared with the control, whereas such enhancement was not detected in GR-N-or GR-C-transfected cells (Fig. 5 Ci and ii) . Finally, the responses to BDNF in cortical neurons transfected with these GR plasmids were examined. PLC-␥ activation and glutamate release in GR-FL-transfected neurons were reinforced; in contrast, neither PLC-␥ activation nor glutamate release was enhanced by GR-N and GR-C transfection (Fig. 5 Di and ii). These results suggest that the N-terminal region of the GR interacts with TrkB; however, the C-terminal region is also required to boost BDNF-activated PLC-␥.
Discussion
We have shown that chronic pretreatment with DEX disturbs BDNF-stimulated PLC-␥ signaling for glutamate release via a glutamate transporter. Chronic DEX caused marked GR downregulation. GR overexpression recovered the reduction in BDNF-activated PLC-␥, and siRNA transfection for endogenous GR mimicked the inhibitory effect of DEX. Corticosterone also reduced the GR level and suppressed BDNF-stimulated PLC-␥ and glutamate release. Interestingly, we found that the GR interacted with TrkB and that the TrkB-GR interaction and the BDNF-dependent binding of PLC-␥ to TrkB decreased following DEX exposure.
BDNF-activated PLC-␥ was specifically down-regulated by DEX or corticosterone whereas the activation of TrkB, Akt (a component of the PI3K pathway), and ERK signaling was not affected. A study on an animal model of depression showed a different responsiveness at the level of PI (phosphoinositide)-PLC after single vs. repeated stress (26) . Additionally, long-term administration of antidepressants (desipramine, fluoxetine, and phenelzine) decreases PI-PLC activity in the membrane and cytosol fractions of the rat cortex (27) . Meanwhile, imipramine activates PLC-␤1 in the rat frontal cortex membrane (28) . Recently, we reported that BDNF-activated PLC-␥ was increased by imipramine (19) . These studies suggest that PLC activity is critical in the pathophysiology of depression and the effects of antidepressants. In isolated rat islets, DEX suppresses PLC activation and insulin secretion (29) . Thus, to reveal the cell biology of stress hormones, it may be valuable to focus on the PLC/Ca 2ϩ system in neuronal or nonneuronal cells.
Glucocorticoids acutely activate TrkB signaling via the genomic function of the GR (25) . Activation of TrkB, PLC-␥, Akt, and ERK was increased by short-term application of DEX and corticosterone, reaching the maximum at 2-4 h after the application, and returned to the baseline in our cultures. In contrast, no change in the BDNF-stimulated activations of TrkB signaling, including PLC-␥, was observed after such a short-term pretreatment with DEX or corticosterone. In this study, decreased responses to BDNF (not response to the glucocorticoid alone) after long-term glucocorticoid exposure (24-48 h) were discovered. Collectively, these results suggest that glucocorticoids play various functions depending on exposure time and that the mechanism underlying the down-regulation of BDNF-dependent PLC-␥ signaling after chronic glucocorticoid exposure differs from the activation of TrkB signaling by acute exposure.
Down-regulations of the GR and TrkB-GR interaction caused by chronic DEX or corticosterone were observed. Such downregulation was also observed in vivo. It is possible that the GR down-regulation may simply result in the decrease of the GR/ TrkB complex. GR-overexpressing neurons showed a high response to BDNF, and siRNA for the GR mimicked the action of DEX, suggesting that moderate levels of GR expression may be essential for the BDNF/TrkB/PLC-␥ system. In this study, a BDNF-dependent slight increase in TrkB-GR interaction in the control cultures was observed. In contrast, f luctuation in TrkB-GR interaction by GR overexpression or down-regulation was observed without BDNF stimulation, and endogenous BDNF was not changed by DEX. Thus, both BDNF (or phosphorylation of TrkB)-dependent and -independent mechanisms might be involved in TrkB-GR interaction.
Glucocorticoids have a rapid influence on intracellular signaling (not via transcriptional activity), and this rapid action is presumed to be mediated via membrane-bound and nonmembrane-bound GR (classical GR) or putative G protein-coupled receptors on a plasma membrane (30, 31) . We speculate that classical GR is involved in TrkB/PLC-␥ signaling because RU486 blocked the inhibitory effect of DEX, and the overexpression and down-regulation of the GR influenced TrkB/PLC-␥ signaling. Raf-1 and 14-3-3 interact with liganded-or nonliganded GR (32) , implying that the GR directly influences signaling pathways in cytosol. Moreover, the GR affects the plasma membrane receptor in immune T-cells (30) . The T cell receptor (TCR) makes a protein complex including the GR. After the glucocorticoid is bound to the GR, the GR dissociates from the complex, and TCR signaling is inhibited. A similar mechanism might be involved in TrkB-GR interaction. Interestingly, FMS-like tyrosine kinase 3 (Flt3), another member of the receptor tyrosine kinase (RTK) family, interacts with the GR in hematopoietic cells (33) . Flt3 interacts with the N-terminal region of the GR in the presence and absence of glucocorticoid. In the present study, TrkB/PLC-␥ signaling was potentiated by GR overexpression and declined by GR down-regulation without DEX, implying that the GR has a positive effect on PLC-␥ signaling in a ligand-independent fashion. In our system, the N-terminal region of the GR interacts with TrkB; however, the C-terminal region is also required for the full activation of PLC-␥. These results, including those of our study, indicate an important role of GR in the signaling of the RTK family.
The influx of Ca 2ϩ regulates BDNF expression (34, 35) . In addition, glutamate can regulate neurotrophin expression (36, 37) . BDNF is produced and released in an activity-dependent manner (38, 39) . Collectively, it is possible that suppression in BDNFstimulated PLC-␥/Ca 2ϩ signaling for glutamate release may be followed by a reduction in BDNF protein. Previously, we found that antidepressants potentiated BDNF-stimulated PLC-␥/Ca 2ϩ (19) . Therefore, our system, in which a glucocorticoid exerts an inhibitory effect on BDNF-stimulated PLC-␥/Ca 2ϩ , may be useful for evaluating novel analogs as antidepressant candidates. Interestingly, the high-affinity interaction of pro-neurotrophin with a low-affinity receptor p75 was reported (40) . It may be valuable to study, not only with respect to the expression of mature BDNF but also in terms of the neurotrophin form (pro-/mature) and the affinity of the ligand/receptor/adaptor interaction (present study) during stress hormone exposure.
Materials and Methods
Cells, Survival Assay, Ca 2؉ Imaging, Immunoprecipitation, Immunoblotting, Immunocytochemistry, and Animals. Cortical neurons were prepared from P2 rats as previously reported (18) . Cell viability was examined with an MTT assay. In Ca 2ϩ imaging, in which fluo-3 dye was used, the ratio (F/F0) of fluorescence was calculated based on the intensities of fluorescence before and after BDNF was added. Immunoprecipitation, immunoblotting, and immunocytochemistry were performed as previously described (18) . For the in vivo approach, P7 rats received an i.p. injection of (0.1-10 mg/kg i.p.) DEX or vehicle (sesame oil). After 48 h, the brains were removed from the deeply anesthetized rats, and the cerebral tissues were homogenized. All animals were treated according to the institutional guidelines for the care and use of animals. Details of these experiments are available in SI Materials and Methods. DEX Pretreatment. After the cortical cultures were maintained for 4 or 5 days, DEX (1 M, BIOMOL International L.P.) or corticosterone (1 M, SIGMA) was added to the neurons by bath application. Subsequently, the cultures were incubated for 24 or 48 h in the presence of DEX or corticosterone before amino acid measurement, Ca 2ϩ imaging, immunoprecipitation, immunoblotting, and immunocytochemistry were performed. DEX or corticosterone was dissolved in DMSO. Sole DMSO (vehicle) had no effects compared with no treatment (data not shown). RU486 (1 M, LKT Laboratories) was applied 20 min before adding DEX.
Detection of Amino Acid Neurotransmitters.
HPLC was used to analyze amino acid neurotransmitters as described previously (18) . Details can be found in SI Materials and Methods. Viral GR Construct, GR Deletion Plasmids, and siRNA. Detailed procedures for constructing the sindbis virus, producing GR plasmids, and transfecting siRNA are described in SI Materials and Methods.
Statistical Analysis. Data are expressed as mean Ϯ SD. Statistical significance was evaluated by student's t test, and probability values of less than 5% were considered significant.
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